The bacterial growth risk is secondarypeptide degradation is the primary failure mode
In Phase 2, weekly subcutaneous CT-388 at 24 mg achieved 22.5% placebo-adjusted weight loss at 48 weeks in 469 adults with obesity, with no plateau observed
Specifically, the FDA warns that compounded drugs containing Selank pose a risk for immunogenicity, a state in which the body perceives a substance as a threat and mounts a potentially life-threatening immune response against it.21 22 The FDA qualifies the risk to certain routes of administration but doesnt specify which routes, and also notes a lack of safety information concerning Selank administered to humans.21 Our relationships with peptide providers have given us additional insights into this topic, but the side effects theyve shared with us are no different from those of most therapeutic peptides weve covered ( injection site reactions , stomach discomfort , nausea , headaches , and dizziness )
Conditions We Treat At Evolve Med Group, we address a wide variety of health and wellness concerns
Adisseo Inc., Antony, France)